XML 31 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segments (Tables)
 3 Months Ended
Mar. 31, 2014
Segment Reporting [Abstract]  
Information regarding our geographic activities
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2014
 
2013
Product revenues:
 
 
 
Pharmaceuticals
$
19,828

 
$
15,527

Diagnostics
—

 
—

Corporate
—

 
—

 
$
19,828

 
$
15,527

Revenue from services:
 
 
 
Pharmaceuticals
$
—

 
$
—

Diagnostics
1,910

 
3,052

Corporate
60

 
40

 
$
1,970

 
$
3,092

Revenue from transfer of intellectual property:
 
 
 
Pharmaceuticals
$
285

 
$
12,500

Diagnostics
191

 
257

Corporate
—

 
—

 
$
476

 
$
12,757

Operating (loss) income:
 
 
 
Pharmaceuticals
$
(16,573
)
 
$
8,483

Diagnostics
(7,078
)
 
(9,634
)
Corporate
(6,137
)
 
(5,025
)
Less: Operating loss attributable to noncontrolling interests
(489
)
 
(597
)
 
$
(30,277
)
 
$
(6,773
)
Depreciation and amortization:
 
 
 
Pharmaceuticals
$
1,849

 
$
1,695

Diagnostics
1,691

 
1,689

Corporate
24

 
45

 
$
3,564

 
$
3,429

Revenues:
 
 
 
United States
$
2,446

 
$
15,849

Chile
7,285

 
7,741

Spain
6,150

 
4,324

Israel
4,546

 
2,572

Mexico
1,831

 
890

Uruguay
16


—

 
$
22,274

 
$
31,376


(In thousands)
March 31,
2014
 
December 31,
2013
Assets:
 
 
 
Pharmaceuticals
$
1,067,848

 
$
1,065,033

Diagnostics
113,515

 
116,944

Corporate
174,329

 
209,539

 
$
1,355,692

 
$
1,391,516

Goodwill:

 

Pharmaceuticals
$
175,097

 
$
175,408

Diagnostics
50,965

 
50,965

Corporate
—

 
—

 
$
226,062

 
$
226,373